Research programme: peptide hybrids - Amylin Pharmaceuticals

Drug Profile

Research programme: peptide hybrids - Amylin Pharmaceuticals

Alternative Names: AC 164209; Amylinomimetic/GRA peptide hybrid; GLP-1 receptor agonist/amylin analogue hybrid; GLP-1 receptor agonist/amylin mimetic hybrid; GLP-1 receptor agonist/amylinomimetic hybrid; GRA/amylinomimetic peptide hybrid; INTO

Latest Information Update: 12 Nov 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Peptides; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 07 Nov 2013 Discontinued - Preclinical for Diabetes mellitus in USA (SC)
  • 07 Nov 2013 Discontinued - Preclinical for Obesity in USA (SC)
  • 25 Dec 2012 Amylin Pharmaceuticals and Takeda terminate their agreement for this research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top